Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
151 hedge funds and large institutions have $1.49B invested in Revance Therapeutics, Inc. in 2020 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 51 increasing their positions, 45 reducing their positions, and 27 closing their positions.
19% more capital invested
Capital invested by funds: $1.25B → $1.49B (+$239M)
13% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 45
4% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 27
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less funds holding
Funds holding: 153 → 151 (-2)
51% less call options, than puts
Call options by funds: $6.53M | Put options by funds: $13.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$73.8M |
| 2 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$17.6M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$12M |
| 4 |
UBS AM
Chicago,
Illinois
|
+$8.61M |
| 5 |
JP Morgan Chase
New York
|
+$6.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$21.3M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$9.24M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.63M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$6.4M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$3.72M |
RVNC Hedge Fund Activity: Q4 2020 in Review
151 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q4 2020, worth a combined $1.49B — up 19% from $1.25B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new RVNC positions and 27 closed out — a net gain of 1 holder — while 51 added to existing stakes and 45 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $73.8M. The largest seller was Franklin Resources, cutting an estimated $21.3M.
- 151 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q4 2020, down from 153 in Q3 2020.
- Funds reported $1.49B of Revance Therapeutics, Inc. stock for Q4 2020, up 19% quarter-over-quarter.
- 28 funds opened new Revance Therapeutics, Inc. positions in Q4 2020 and 27 closed out, a net change of +1 holder.
- The largest Revance Therapeutics, Inc. buyer in Q4 2020 was Fidelity Investments, an estimated $73.8M added.
- The largest Revance Therapeutics, Inc. seller in Q4 2020 was Franklin Resources, an estimated $21.3M sold.
Based on aggregated 13F filings for Q4 2020.